184 related articles for article (PubMed ID: 34865819)
1. Routine use of LMWH prophylaxis is associated with a lower incidence of venous thromboembolic events following an ankle fracture.
Juto H; Hultin M; Möller M; Morberg P
Injury; 2022 Feb; 53(2):732-738. PubMed ID: 34865819
[TBL] [Abstract][Full Text] [Related]
2. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
3. Chemoprophylaxis for venous thromboembolism in pelvic and/or acetabular fractures: A systematic review.
Shu HT; Yu AT; Lim PK; Scolaro JA; Shafiq B
Injury; 2022 Apr; 53(4):1449-1454. PubMed ID: 35148902
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
6. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials.
Chapelle C; Rosencher N; Jacques Zufferey P; Mismetti P; Cucherat M; Laporte S;
Arthroscopy; 2014 Aug; 30(8):987-96. PubMed ID: 24813323
[TBL] [Abstract][Full Text] [Related]
7. Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin.
Haac BE; Van Besien R; O'Hara NN; Slobogean GP; Manson TT; O'Toole RV; Johal H; Berger PZ; Reahl GB; Marinos D; Degani Y; Mascarenhas D; Connelly D; Scalea TM; Stein DM
J Trauma Acute Care Surg; 2018 Apr; 84(4):564-574. PubMed ID: 29251700
[TBL] [Abstract][Full Text] [Related]
8. The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis.
Milbrink J; Bergqvist D
Vasa; 2008 Nov; 37(4):353-7. PubMed ID: 19003746
[TBL] [Abstract][Full Text] [Related]
9. The incidence and risk factors of recurrent venous thromboembolism during pregnancy.
Galambosi PJ; Ulander VM; Kaaja RJ
Thromb Res; 2014 Aug; 134(2):240-5. PubMed ID: 24835671
[TBL] [Abstract][Full Text] [Related]
10. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the use of low-molecular-weight heparin for venous thromboembolism prophylaxis in medical patients.
Du Plessis JA; Van Blydenstein SA; Wong M
S Afr Med J; 2020 Feb; 110(3):235-242. PubMed ID: 32657702
[TBL] [Abstract][Full Text] [Related]
13. Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Arthroscopic Surgery and Anterior Cruciate Ligament Reconstruction: A Meta-analysis of Randomized Controlled Trials.
Zhu J; Jiang H; Marshall B; Li J; Tang X
Am J Sports Med; 2019 Jul; 47(8):1994-2002. PubMed ID: 30113231
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
Marciniak CM; Kaplan J; Welty L; Chen D
PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture.
Gouzoulis MJ; Joo PY; Kammien AJ; McLaughlin WM; Yoo B; Grauer JN
PLoS One; 2022; 17(10):e0276548. PubMed ID: 36264985
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin versus unfractionated heparin in pediatric traumatic brain injury.
van Erp IA; Gaitanidis A; El Moheb M; Kaafarani HMA; Saillant N; Duhaime AC; Mendoza AE
J Neurosurg Pediatr; 2021 Feb; 27(4):469-474. PubMed ID: 33578391
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin prophylaxis is not associated with decreased incidence of venous thromboembolism in testicular germ cell tumor patients receiving chemotherapy.
Hapakova N; Chovanec M; Rejlekova K; Kalavska K; Obertova J; Palacka P; De Angelis V; Sycova-Mila Z; Mardiak J; Mego M
Neoplasma; 2022 Mar; 69(2):456-463. PubMed ID: 35068164
[TBL] [Abstract][Full Text] [Related]
18. Effect of Chemical Thromboprophylaxis on the Rate of Venous Thromboembolism After Treatment of Foot and Ankle Fractures.
Zheng X; Li DY; Wangyang Y; Zhang XC; Guo KJ; Zhao FC; Pang Y; Chen YX
Foot Ankle Int; 2016 Nov; 37(11):1218-1224. PubMed ID: 27521353
[TBL] [Abstract][Full Text] [Related]
19. Body Mass Index and Pharmacologic Venous Thromboembolism Prophylaxis in Traumatic Brain Injury.
Filiberto DM; Byerly S; Lenart EK; Fischer PE; Kerwin AJ
J Surg Res; 2023 Nov; 291():245-249. PubMed ID: 37478648
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis in Ambulatory Trauma Patients With Foot and Ankle Fractures: Prospective Study Using a Risk Scoring System.
Haque S; Bishnoi A; Khairandish H; Menon D
Foot Ankle Spec; 2016 Oct; 9(5):388-93. PubMed ID: 27044599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
